newsfilter
← Latest News
PR Newswire·

Telix to Participate in UBS Global Biopharma Conference

  • Telix Pharmaceuticals Limited will participate in the UBS Global Biopharma Conference in London, UK.
  • Managing Director and Group CEO Dr. Christian Behrenbruch and CEO Therapeutics Mr. Richard Valeix will attend a fireside chat on Tuesday, November 17, 2026, at 9:20 a.m. GMT.
  • The session will be webcast live via Telix's Investor Relations website, with registration available at ir.telixpharma.com/events-presentations.
  • Telix is a commercial-stage global radiopharmaceutical company headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America, Asia-Pacific.
  • The company's commercial franchise includes Illuccix, Gozellix (FDA-approved for prostate imaging), and Pixclara (FDA-approved for glioma imaging).
  • Telix's late-stage pipeline features three pivotal assets: TLX591-Tx for prostate cancer, TLX101-Tx for recurrent glioblastoma, and TLX250-Tx for kidney cancer.
  • Investor relations contact is Annie Kasparian, media contact is Eliza Schleifstein, with Charlene Jaw also listed for investor inquiries.
  • The announcement includes standard legal disclaimers regarding forward-looking statements, risks, uncertainties, trademark ownership, and information accuracy.
Company
Telix Pharmaceuticals Limited
Keywords
Telix Pharmaceuticals Limited